S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
APRE · Aprea Therapeutics, Inc. Common stock
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Aprea Therapeutics Inc (APRE)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.53
-0.01
(-2.65%)
● At close: October 20 at 4:00:00 PM EDT
DAY'S RANGE
$0.53
$0.52
$0.54
52-WEEK RANGE
$0.53
$0.53
$1.69
What's happening
- APRE is down 2.65% today, trading at $0.53. — Live quote
- It's trading within 3% of its 52-week low ($0.53). (Finnhub fundamentals)
- Volume today (13,371) is well below its 3-month average of 231,560. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.07 actual vs. $-0.24 estimated (+70.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
APRE
-37.60%
vs S&P 500
-50.00%
1-YEAR RETURN
APRE
-66.10%
vs S&P 500
-81.46%
6-MONTH RETURN
APRE
-43.55%
3-MONTH RETURN
APRE
-20.43%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.07
Est. $-0.24
BEAT +70.8%
2026-04-26 (Q1 2026)
$-0.22
Est. $-0.23
BEAT +6.2%
2026-01-26 (Q4 2025)
$-0.32
Est. $-0.40
BEAT +19.6%
2025-10-26 (Q3 2025)
$-0.47
Est. $-0.35
MISS -36.1%
Valuation Measures & Ratios
Enterprise Value4-$34.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)24.81
Price / Book70.25
EV4 / Revenue-119.49
EV4 / EBITDA—
Profit Margin-4409.14%
Operating Margin-4631.10%
Return on Equity (ROE8)-46.30%
Return on Assets (ROA9)-40.97%
Avg Volume (3M)231,560
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $39.3M | $11.8M | $9.4M | $10.4M | $12.2M |
| P/E | -3.00 | -0.88 | -0.67 | -0.72 | -0.87 |
| Price/Book | 1.02 | 0.28 | 0.86 | 0.77 | 0.79 |
| EV/EBITDA | 0.14 | 2.48 | 0.30 | — | — |
| ROE | -34.03% | -32.30% | -127.63% | -107.53% | -90.01% |
| ROA | -30.95% | -28.21% | -97.25% | -83.34% | -69.21% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short508,841
Change from Prior Settlement-11.45%
% of Float—
Days to Cover (Short Ratio)2.45
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-28; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -4409.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -66.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on APRE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$4.0M | -$3.4M | -$3.1M | -$3.4M | -$4.1M | -$4.1M | -$3.8M | -$3.1M |
| Net income | -$3.6M | -$3.3M | -$3.0M | -$3.2M | -$3.9M | -$3.8M | -$3.5M | -$2.8M |
| EPS (diluted) | $-0.07 | $-0.22 | $-0.47 | $-0.53 | $-0.66 | $-0.64 | $-0.58 | $-0.67 |
| EPS (basic) | $-0.07 | $-0.22 | $-0.47 | $-0.53 | $-0.66 | $-0.64 | $-0.58 | $-0.67 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $42.3M | $47.6M | $15.9M | $14.3M | $17.3M | $20.2M | $24.0M | $26.9M |
| Total liabilities | — | — | — | — | — | — | — | — |
| Stockholders' equity | $38.5M | $41.6M | $12.4M | $10.9M | $13.4M | $15.5M | $19.3M | $21.9M |
| Total current assets | $41.9M | $47.2M | $15.6M | $13.9M | $16.9M | $19.8M | $23.6M | $26.5M |
| Total current liabilities | $3.1M | $5.3M | $2.8M | $2.7M | $3.2M | $3.4M | $3.4M | $3.6M |
| Cash & equivalents | $41.2M | $46.5M | $14.6M | $13.7M | $16.5M | $19.3M | $22.8M | $26.2M |
| Property, plant & equipment | $64.0K | $54.4K | $59.8K | $65.2K | $70.7K | $76.1K | $81.5K | $87.0K |
| Other non-current assets | $271.2K | $271.2K | $271.2K | $271.2K | $271.2K | $271.2K | $281.7K | $281.7K |
| Accounts payable | $935.1K | $2.9M | $713.7K | $641.3K | $1.2M | $1.3M | $1.4M | $1.2M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $12.4K | $12.0K | $8.2K | $6.0K | $5.8K | $5.5K | $5.5K | $5.4K |
| Retained earnings | -$340.5M | -$336.9M | -$333.6M | -$331.2M | -$328.2M | -$325.0M | -$321.0M | -$318.1M |
| Accumulated other comprehensive income (loss) | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.3M | -$2.8M | -$3.0M | -$3.2M | -$3.1M | -$3.6M | -$3.5M | -$2.5M |
| Investing cash flow | -$15.4K | — | — | — | — | — | $0 | $0 |
| Financing cash flow | -$1.9M | $34.6M | $3.8M | $357.9K | $384.9K | $55.8K | $134.4K | -$1.2K |
| Free cash flow | -$3.3M | — | — | — | — | — | -$3.5M | -$2.5M |
| Capital expenditures | $15.4K | — | — | — | — | — | $0 | $0 |
| Depreciation & amortization | $5.7K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K |
| Change in accounts payable | $189.8K | $32.5K | $68.9K | -$554.0K | -$89.7K | -$71.9K | $201.8K | $187.5K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M |
| EPS (diluted) | $-1.93 | $-2.35 | $-3.95 | $-67.99 | $-34.88 |
| EPS (basic) | $-1.93 | $-2.35 | $-3.95 | $-67.99 | $-34.88 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M |
| Total liabilities | — | — | — | $3.2M | $7.3M |
| Stockholders' equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M |
| Total current assets | $15.6M | $23.6M | $22.5M | $30.2M | $56.6M |
| Total current liabilities | $2.8M | $3.4M | $4.4M | $3.2M | $7.3M |
| Cash & equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M |
| Property, plant & equipment | $59.8K | $81.5K | $88.4K | $2.3K | $23.9K |
| Other non-current assets | $271.2K | $281.7K | — | — | $29.4K |
| Accounts payable | $713.7K | $1.4M | $1.7M | $842.8K | $1.8M |
| Deferred revenue (current) | — | — | $529.0K | — | — |
| Common stock & paid-in capital | $8.2K | $5.5K | $3.7K | $2.7K | $1.1K |
| Retained earnings | -$333.6M | -$321.0M | -$308.1M | -$293.8M | -$181.1M |
| Accumulated other comprehensive income (loss) | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.4M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M |
| Investing cash flow | — | -$15.5K | -$93.1K | — | — |
| Financing cash flow | $4.6M | $14.8M | $5.1M | $683.0K | $1.7M |
| Free cash flow | — | -$13.6M | -$12.3M | — | — |
| Capital expenditures | — | $15.5K | $93.1K | — | — |
| Depreciation & amortization | $21.7K | $22.3K | $7.1K | $4.4K | $12.8K |
| Change in accounts payable | -$646.7K | -$314.2K | $827.5K | -$858.5K | -$2.7M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding APRE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-05 to 2026-06-16
Recent transactions
- Most recent: Grissinger Michael (Director) — Grant / award of 3,135 shares on 2026-06-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Grissinger Michael | Director | Grant / award | 2026-06-16 | 3,135 |
| Gruia Gabriela | Director | Grant / award | 2026-06-16 | 3,135 |
| Peters Richard | Director | Grant / award | 2026-06-16 | 3,135 |
| HENNEMAN JOHN B III | Director | Grant / award | 2026-06-16 | 3,135 |
| BIZZARI JEAN-PIERRE | Director | Grant / award | 2026-06-16 | 3,135 |
| Duey Marc | Director | Grant / award | 2026-06-16 | 3,135 |
| Pamukcu Rifat | Director | Grant / award | 2026-06-16 | 3,135 |
| Seizinger Bernd R. | Director | Grant / award | 2026-06-16 | 3,135 |
| Gilad Oren | President/CEO | Grant / award | 2026-03-12 | 20,175 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant / award | 2026-03-12 | 10,095 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-16 | Grissinger Michael | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | Gruia Gabriela | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | Peters Richard | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | HENNEMAN JOHN B III | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | BIZZARI JEAN-PIERRE | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | Duey Marc | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | Pamukcu Rifat | Director | Grant / award | 3,135 | $0.00 |
| 2026-06-16 | Seizinger Bernd R. | Director | Grant / award | 3,135 | $0.00 |
| 2026-03-12 | Gilad Oren | President/CEO | Grant / award | 20,175 | $0.00 |
| 2026-03-12 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant / award | 10,095 | $0.00 |
| 2026-01-30 | Gilad Oren | President/CEO | Open market purchase | 28,100 | $0.89 |
| 2026-01-30 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Open market purchase | 5,700 | $0.89 |
| 2025-12-10 | Duey Marc | Director | Open market purchase | 21,459 | $1.17 |
| 2025-12-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Open market purchase | 5,000 | $1.17 |
| 2025-06-05 | Seizinger Bernd R. | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | Peters Richard | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | Pamukcu Rifat | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | HENNEMAN JOHN B III | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | Gruia Gabriela | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | Grissinger Michael | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | Duey Marc | Director | Grant / award | 1,045 | $0.00 |
| 2025-06-05 | BIZZARI JEAN-PIERRE | Director | Grant / award | 1,045 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-28 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-23 | 8-K | 2026-07-23 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
Recent news
Headlines about APRE (Aprea Therapeutics, Inc. Common stock). Links open the publisher — we don’t host full articles.
-
Aprea Therapeutics Q3 2026 Earnings Date and Estimates
MarketBeat · 2026-10-18 -
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Yahoo · 2026-10-16 -
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2
Benzinga · 2026-10-14 -
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 2026-10-08 -
Aprea Therapeutics to Present at October Conferences
Yahoo Finance · 2026-10-05 -
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Yahoo Finance · 2026-09-22 -
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-10 -
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Yahoo Finance · 2026-08-28
No headlines in this category right now — try “All”.